ZZPZH(SH:600436) Xin Hua Cai Jing·2025-12-02 07:05Core Viewpoint - Zhangzhou Pianzaihuang Pharmaceutical Co., Ltd. (stock code: 600436.SH) has been awarded the "Golden Bull Most Investment Value Award" for 2024, recognizing its comprehensive strength and continuous improvement in investment value [1][2] Group 1: Awards and Recognition - The "Golden Bull Most Investment Value Award" is one of the most authoritative awards in the capital market, evaluating companies based on 18 key indicators across six dimensions: scale, profitability, solvency, asset management, growth, and innovation [1] - Pianzaihuang has received the Golden Bull series awards for several consecutive years, highlighting its consistent performance [1] Group 2: Financial Performance and Dividends - For the 2024 fiscal year, the company will distribute a cash dividend of 2.97 yuan per share (before tax), totaling 1.79 billion yuan, marking a historical high and representing 60% of its net profit [1] - Since its listing in 2003, the company has implemented cash dividends for 21 consecutive years, with cumulative cash dividends amounting to nearly 8.5 billion yuan [1] Group 3: Brand Value and R&D - As a time-honored brand, Pianzaihuang ranks second in brand value among "Chinese Time-Honored Brands" with a value of 42.289 billion yuan, showing a year-on-year increase [2] - The company has topped the "Hurun Brand List for Chinese Medical Health Brand Value" for four consecutive years [2] - In 2024, R&D investment reached 270 million yuan, a year-on-year increase of 16.38%, focusing on secondary development research of its advantageous products [2] Group 4: Future Development Strategy - Pianzaihuang aims to leverage this award as a new starting point to continue its development philosophy of "Upholding Integrity and Innovation, Steady and Far-reaching" [2] - The company plans to strengthen its core product advantages and expand its market presence in cosmetics, daily chemicals, and health food sectors, contributing to the broader health industry [2]